Y-mAbs TherapeuticsAktie

ISIN: US9842411095 | WKN: A2N5R0 | Symbol: YMAB
41,74
 
USD
02:00:00 Nasdaq
+0,34 %
+0,14 USD
Geldkurs 08.07.20
41,61 USD
1.000 Stk.
Briefkurs 08.07.20
41,77 USD
600 Stk.
Mehr Daten anzeigen
Smartbroker
NewsFlashAnzeige
Goldminenaktie vor neuer Kaufwelle? Diese News könnten der Auslöser sein!

Y-mAbs Therapeutics Chart

Neuigkeiten zur Y-mAbs Therapeutics Inc Aktie

ZeitTitel
SmartbrokerJetzt auf smartbroker.de - ab 0 € pro Order handeln! Anzeige
30.06.20

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA
02.06.20

Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza (naxitamab) for the Treatment of Neuroblastoma for Priority Review
13.05.20

Y-mAbs Announces Data to be Presented at 2020 ASCO Annual Meeting
07.05.20

Y-mAbs Announces First Quarter 2020 Financial Results and Recent Corporate Developments
30.04.20

UPDATE - Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020
30.04.20

Y-mAbs to Announce 2019 Financial and Operating Results on May 7, 2020
24.04.20

Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors
15.04.20

Y-mAbs enters into Worldwide Exclusive License Agreement for SADA Technology – a Novel Radioimmunotherapy Platform
01.04.20

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
12.03.20

Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments
05.03.20

Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020
26.02.20

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab
07.01.20

Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference
12.12.19

Y-mAbs’ GD2-GD3 Vaccine Granted Rare Pediatric Disease Designation

Insidertrade: :
Hier Upload von Dokumenten / Links zum Wertpapier: Upload

Nachrichten aus der Branche Biotechnologie

ZeitTitel
00:13 Uhr
First Extensive Validation Study of Saphyr for Constitutional Genetic Disorders by European Consortium Shows 100% Concordance to Standard Cytogenetics and Describes Resolution of Cases of Long-Standing, Undiagnosed Disease
08.07.20
Inventiva announces the filing of an amended registration statement, including an estimated initial public offering price range
08.07.20
10x Genomics to Report Second Quarter Financial Results on August 11, 2020
08.07.20
CytoDyn to Present at Wall Street Reporter’s Livestream Event on July 9, 2020 at 1: 30 pm ET / 10:30 am PT
08.07.20
Zymeworks Corporate Update Webcast and Conference Call Summary
mehr Branchennachrichten »

Aktienkurs Y-mAbs Therapeutics A2N5R0 |

BörsenplatzNasdaq
Letzter Kurs41,74USD
Performance+0,34 %
Kurszeit02:00:00
Eröffnung32,55USD
Tageshoch42,05USD
Tagestief32,55USD
Vortageskurs41,60USD
Volumen125,34 Tsd.Stk.
52-Wochen Hoch50,49USD
52-Wochen Tief14,160USD
Anzahl Trades783
Performance 1 Monat-6,60 %
Performance 1 Jahr+84,40 %

Stammdaten zu Y-mAbs Therapeutics

NameY-mAbs Therapeutics Inc
KurznameY-mAbs Therap
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2N5R0
SymbolYMAB
BrancheBiotechnologie
LandUSA USA
ReferenzwährungUSD
Aktienanzahl39,76 Mio.
Marktkapitalisierung1,66 Mrd.USD

Performance Y-mAbs Therapeutics Aktie

ZeitKursPerf.
1 Tag41,74USD
+0,34 %
1 Woche42,08USD
-1,14 %
1 Monat44,54USD
-6,60 %
3 Monate27,83USD
+49,48 %
6 Monate31,43USD
+32,36 %
Lfd. Jahr31,25USD
+33,12 %
1 Jahr22,560USD
+84,40 %
mehr Performancedaten »
Adresse und Kontaktdaten
NameY-mAbs Therapeutics Inc
StadtNew York, NY
LandUSA USA
Webseitewww.ymabs.com
Aktionäre interessieren sich auch für:
#WertpapierPerf. %
1.
Amgen
-0,62
2.
Kopin
+2,40
3.
Novartis
0,00
 
4.
Thermo Fisher Scientific
+0,54
5.
Roche Holding
0,00
 
6.
Mednax
+0,69
7.
AbbVie
-0,07
8.
Wayfair Registered (A)
-2,11
9.
Remark Holdings
-2,65
10.
KLX Energy Services Holdings
+5,21

Emissionsinformationen

Ausgabepreis14,00USD - 16,00USD
Emissionspreis16,000USD
Emissionsvolumen5.333.333Stück
ZeichnungsgebührNein
IPO Anmeldetag24.08.2018
IPO21.09.2018
PlatzierungÖffentlich